The initial success of the copyright undeniably reshaped the drug landscape, but betting in companies primarily reliant on unbranded versions presents a uncertain picture. While early profits were significant, the cessation of patents and the emergence of discounted alternatives have eroded sales. Thus, a thorough analysis of current revenue stream